Literature DB >> 19002653

Emergency reversal of antithrombotic treatment.

Marcel Levi1.   

Abstract

The most important adverse effect of antithrombotic treatment is the occurrence of bleeding. In case of serious or even life-threatening bleeding in a patient who uses anticoagulant agents or when a patient on anticoagulants needs to undergo an urgent invasive procedure, anticoagulant treatment can be reversed by various specific strategies. Heparin and heparin derivatives can be counteracted by protamine sulphate, whereas the anticoagulant effect of vitamin K antagonists may be neutralized by administration of vitamin K or prothrombin complex concentrates. The anti-hemostatic effect of aspirin and other anti-platelet strategies can be corrected by the administration of platelet concentrate or desmopressin, if needed. Recently, a new generation of anticoagulants with a greater specificity towards activated coagulation factors has been introduced and most of these agents are presently being evaluated in clinical studies. The new generation anticoagulants include specific inhibitors of factor IIa, factor Xa (including pentasaccharides) and agents that interfere with tissue factor activity. A limitation of this new class of anticoagulants may be the lack of an appropriate strategy to reverse the effect if a bleeding event occurs, although in some cases the administration of recombinant factor VIIa may be an option.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19002653     DOI: 10.1007/s11739-008-0201-8

Source DB:  PubMed          Journal:  Intern Emerg Med        ISSN: 1828-0447            Impact factor:   3.397


  77 in total

1.  A comparison of the efficacy and rate of response to oral and intravenous Vitamin K in reversal of over-anticoagulation with warfarin.

Authors:  H G Watson; T Baglin; S L Laidlaw; M Makris; F E Preston
Journal:  Br J Haematol       Date:  2001-10       Impact factor: 6.998

2.  Recombinant nematode anticoagulant protein c2, an inhibitor of the tissue factor/factor VIIa complex, in patients undergoing elective coronary angioplasty.

Authors:  Arno H M Moons; Ron J G Peters; Nick R Bijsterveld; Jan J Piek; Martin H Prins; George P Vlasuk; William E Rote; Harry R Büller
Journal:  J Am Coll Cardiol       Date:  2003-06-18       Impact factor: 24.094

Review 3.  Apixaban, an oral, direct inhibitor of activated Factor Xa.

Authors:  Eduard Shantsila; Gregory Y H Lip
Journal:  Curr Opin Investig Drugs       Date:  2008-09

4.  Antiplatelet drugs: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).

Authors:  Carlo Patrono; Colin Baigent; Jack Hirsh; Gerald Roth
Journal:  Chest       Date:  2008-06       Impact factor: 9.410

5.  In vitro reversal of heparin effect with heparinase: evaluation with whole blood prothrombin time and activated partial thromboplastin time in cardiac surgical patients.

Authors:  G J Despotis; A L Summerfield; J H Joist; L T Goodnough; S A Santoro; J J Zimmermann; D G Lappas
Journal:  Anesth Analg       Date:  1994-10       Impact factor: 5.108

6.  Neutralization of enoxaparine-induced bleeding by protamine sulfate.

Authors:  J Van Ryn-McKenna; L Cai; F A Ofosu; J Hirsh; M R Buchanan
Journal:  Thromb Haemost       Date:  1990-04-12       Impact factor: 5.249

7.  A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.

Authors: 
Journal:  Lancet       Date:  1996-11-16       Impact factor: 79.321

Review 8.  Treatment of warfarin-associated intracerebral hemorrhage: literature review and expert opinion.

Authors:  Maria I Aguilar; Robert G Hart; Carlos S Kase; William D Freeman; Barbara J Hoeben; Rosa C García; Jack E Ansell; Stephan A Mayer; Bo Norrving; Jonathan Rosand; Thorsten Steiner; Eelco F M Wijdicks; Takenori Yamaguchi; Masahiro Yasaka
Journal:  Mayo Clin Proc       Date:  2007-01       Impact factor: 7.616

Review 9.  Recombinant activated factor VII: its mechanism of action and role in the control of hemorrhage.

Authors:  Geoffrey A Allen; Maureane Hoffman; Harold R Roberts; Dougald M Monroe
Journal:  Can J Anaesth       Date:  2002-12       Impact factor: 5.063

10.  Desmopressin antagonizes the in vitro platelet dysfunction induced by GPIIb/IIIa inhibitors and aspirin.

Authors:  Rosemarie A Reiter; Florian Mayr; Hannes Blazicek; Elisabeth Galehr; Petra Jilma-Stohlawetz; Hans Domanovits; Bernd Jilma
Journal:  Blood       Date:  2003-08-14       Impact factor: 22.113

View more
  8 in total

Review 1.  [Pertrochanteric femoral fractures in the elderly].

Authors:  G H Sandmann; P Biberthaler
Journal:  Unfallchirurg       Date:  2015-05       Impact factor: 1.000

2.  Correction of coagulopathy for percutaneous interventions.

Authors:  Charles Wiltrout; Kimi L Kondo
Journal:  Semin Intervent Radiol       Date:  2010-12       Impact factor: 1.513

Review 3.  [Old and new anticoagulants. Antidotes and measures for acute hemorrhaging and urgent interventions].

Authors:  M Lancé; B Stessel; K Hamulyák; M A Marcus
Journal:  Anaesthesist       Date:  2010-01       Impact factor: 1.041

Review 4.  [Perioperative management of patients with coronary stents in non-cardiac surgery].

Authors:  C Jámbor; M Spannagl; B Zwissler
Journal:  Anaesthesist       Date:  2009-10       Impact factor: 1.041

Review 5.  The perioperative management of treatment with anticoagulants and platelet aggregation inhibitors.

Authors:  Axel Schlitt; Csilla Jámbor; Michael Spannagl; Wiebke Gogarten; Tom Schilling; Bernhard Zwissler
Journal:  Dtsch Arztebl Int       Date:  2013-08-05       Impact factor: 5.594

Review 6.  A review of current methods for assessing hemostasis in vivo and introduction to a potential alternative approach.

Authors:  Mallory R Scola; Leslie M Baggesen; Tim C Nichols; Nigel S Key; Caterina M Gallippi
Journal:  Thromb Res       Date:  2012-03-08       Impact factor: 3.944

Review 7.  Benefits and harms of 4-factor prothrombin complex concentrate for reversal of vitamin K antagonist associated bleeding: a systematic review and meta-analysis.

Authors:  Marjolein P A Brekelmans; Kim van Ginkel; Joost G Daams; Barbara A Hutten; Saskia Middeldorp; Michiel Coppens
Journal:  J Thromb Thrombolysis       Date:  2017-07       Impact factor: 2.300

Review 8.  Reinforcement Learning for Clinical Decision Support in Critical Care: Comprehensive Review.

Authors:  Siqi Liu; Kay Choong See; Kee Yuan Ngiam; Leo Anthony Celi; Xingzhi Sun; Mengling Feng
Journal:  J Med Internet Res       Date:  2020-07-20       Impact factor: 5.428

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.